<VariationArchive VariationID="159742" VariationName="NM_003560.4(PLA2G6):c.1674del (p.Leu560fs)" VariationType="Deletion" Accession="VCV000159742" Version="8" RecordType="classified" NumberOfSubmissions="3" NumberOfSubmitters="3" DateLastUpdated="2024-06-23" DateCreated="2014-11-23" MostRecentSubmission="2023-02-07">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="169785" VariationID="159742">
      <GeneList>
        <Gene Symbol="PLA2G6" FullName="phospholipase A2 group VI" GeneID="8398" HGNC_ID="HGNC:9039" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>22q13.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="22" Accession="NC_000022.11" start="38111495" stop="38181830" display_start="38111495" display_stop="38181830" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="22" Accession="NC_000022.10" start="38507501" stop="38577835" display_start="38507501" display_stop="38577835" Strand="-" />
          </Location>
          <OMIM>603604</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_003560.4(PLA2G6):c.1674del (p.Leu560fs)</Name>
      <CanonicalSPDI>NC_000022.11:38120826:CCCC:CCC</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>22q13.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="22" Accession="NC_000022.11" start="38120827" stop="38120827" display_start="38120827" display_stop="38120827" variantLength="1" positionVCF="38120826" referenceAlleleVCF="GC" alternateAlleleVCF="G" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="22" Accession="NC_000022.10" start="38516834" stop="38516834" display_start="38516834" display_stop="38516834" variantLength="1" positionVCF="38516833" referenceAlleleVCF="GC" alternateAlleleVCF="G" />
      </Location>
      <OtherNameList>
        <Name>NM_003560.4(PLA2G6):c.1674del</Name>
        <Name>p.Leu560fs</Name>
      </OtherNameList>
      <ProteinChange>L334fs</ProteinChange>
      <ProteinChange>L382fs</ProteinChange>
      <ProteinChange>L328fs</ProteinChange>
      <ProteinChange>L506fs</ProteinChange>
      <ProteinChange>L560fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000022.10" sequenceAccession="NC_000022" sequenceVersion="10" change="g.38516837del" Assembly="GRCh37">
            <Expression>NC_000022.10:g.38516837del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000022.11" sequenceAccession="NC_000022" sequenceVersion="11" change="g.38120830del" Assembly="GRCh38">
            <Expression>NC_000022.11:g.38120830del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_007094.3" sequenceAccession="NG_007094" sequenceVersion="3" change="g.98952del">
            <Expression>NG_007094.3:g.98952del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001004426.3" sequenceAccession="NM_001004426" sequenceVersion="3" change="c.1512del">
            <Expression>NM_001004426.3:c.1512del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001004426.1" sequenceAccession="NP_001004426" sequenceVersion="1" change="p.Leu506fs">
            <Expression>NP_001004426.1:p.Leu506fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001199562.3" sequenceAccession="NM_001199562" sequenceVersion="3" change="c.1512del">
            <Expression>NM_001199562.3:c.1512del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001186491.1" sequenceAccession="NP_001186491" sequenceVersion="1" change="p.Leu506fs">
            <Expression>NP_001186491.1:p.Leu506fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001349864.2" sequenceAccession="NM_001349864" sequenceVersion="2" change="c.1674del">
            <Expression>NM_001349864.2:c.1674del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001336793.1" sequenceAccession="NP_001336793" sequenceVersion="1" change="p.Leu560fs">
            <Expression>NP_001336793.1:p.Leu560fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001349865.2" sequenceAccession="NM_001349865" sequenceVersion="2" change="c.1512del">
            <Expression>NM_001349865.2:c.1512del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001336794.1" sequenceAccession="NP_001336794" sequenceVersion="1" change="p.Leu506fs">
            <Expression>NP_001336794.1:p.Leu506fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001349866.2" sequenceAccession="NM_001349866" sequenceVersion="2" change="c.1512del">
            <Expression>NM_001349866.2:c.1512del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001336795.1" sequenceAccession="NP_001336795" sequenceVersion="1" change="p.Leu506fs">
            <Expression>NP_001336795.1:p.Leu506fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001349867.2" sequenceAccession="NM_001349867" sequenceVersion="2" change="c.1140del">
            <Expression>NM_001349867.2:c.1140del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001336796.1" sequenceAccession="NP_001336796" sequenceVersion="1" change="p.Leu382fs">
            <Expression>NP_001336796.1:p.Leu382fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001349868.2" sequenceAccession="NM_001349868" sequenceVersion="2" change="c.996del">
            <Expression>NM_001349868.2:c.996del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001336797.1" sequenceAccession="NP_001336797" sequenceVersion="1" change="p.Leu334fs">
            <Expression>NP_001336797.1:p.Leu334fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001349869.2" sequenceAccession="NM_001349869" sequenceVersion="2" change="c.978del">
            <Expression>NM_001349869.2:c.978del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001336798.1" sequenceAccession="NP_001336798" sequenceVersion="1" change="p.Leu328fs">
            <Expression>NP_001336798.1:p.Leu328fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_003560.4" sequenceAccession="NM_003560" sequenceVersion="4" change="c.1674del" MANESelect="true">
            <Expression>NM_003560.4:c.1674del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_003551.2" sequenceAccession="NP_003551" sequenceVersion="2" change="p.Leu560fs">
            <Expression>NP_003551.2:p.Leu560fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_1015" sequenceAccession="LRG_1015">
            <Expression>LRG_1015:g.98952del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_1015t1" sequenceAccession="LRG_1015t1">
            <Expression>LRG_1015t1:c.1674del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="LRG_1015p1" sequenceAccession="LRG_1015p1" change="p.Leu560fs">
            <Expression>LRG_1015p1:p.Leu560fs</Expression>
          </ProteinExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="CA173223" DB="ClinGen" />
        <XRef Type="rs" ID="587784336" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_003560.4(PLA2G6):c.1674del (p.Leu560fs) AND Iron accumulation in brain" Accession="RCV000147297" Version="6">
        <ClassifiedConditionList TraitSetID="20141">
          <ClassifiedCondition DB="MedGen" ID="C4021076">Iron accumulation in brain</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2014-03-17" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_003560.4(PLA2G6):c.1674del (p.Leu560fs) AND multiple conditions" Accession="RCV002505128" Version="1">
        <ClassifiedConditionList TraitSetID="10340">
          <ClassifiedCondition DB="MedGen" ID="C2751842">Autosomal recessive Parkinson disease 14</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0270724">Infantile neuroaxonal dystrophy</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C1857747">Neurodegeneration with brain iron accumulation 2B</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2021-11-05" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_003560.4(PLA2G6):c.1674del (p.Leu560fs) AND PLA2G6-associated neurodegeneration" Accession="RCV002514835" Version="3">
        <ClassifiedConditionList TraitSetID="33682">
          <ClassifiedCondition DB="MedGen" ID="CN204472">PLA2G6-associated neurodegeneration</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-01-24" SubmissionCount="1">Likely pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-01-24" NumberOfSubmissions="3" NumberOfSubmitters="3" DateCreated="2014-11-23" MostRecentSubmission="2023-02-07">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic/Likely pathogenic</Description>
        <DescriptionHistory Dated="2023-02-02">
          <Description>Pathogenic</Description>
        </DescriptionHistory>
        <ConditionList>
          <TraitSet ID="33682" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="18389" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">phospholipase A2-associated neurodegeneration</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">PLA2G6-associated neurodegeneration</ElementValue>
                <XRef ID="MONDO:0017998" DB="MONDO" />
                <XRef ID="329303" DB="Orphanet" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">PLAN</ElementValue>
                <XRef Type="MIM" ID="256600" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="12567" />
                <XRef ID="12567" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">PLA2G6-associated neurodegeneration (PLAN) comprises a continuum of three phenotypes with overlapping clinical and radiologic features: Infantile neuroaxonal dystrophy (INAD). Atypical neuroaxonal dystrophy (atypical NAD). PLA2G6-related dystonia-parkinsonism. INAD usually begins between ages six months and three years with psychomotor regression or delay, hypotonia, and progressive spastic tetraparesis. Many affected children never learn to walk or lose the ability shortly after attaining it. Strabismus, nystagmus, and optic atrophy are common. Disease progression is rapid, resulting in severe spasticity, progressive cognitive decline, and visual impairment. Many affected children do not survive beyond their first decade. Atypical NAD shows more phenotypic variability than INAD. In general, onset is in early childhood but can be as late as the end of the second decade. The presenting signs may be gait instability, ataxia, or speech delay and autistic features, which are sometimes the only evidence of disease for a year or more. Strabismus, nystagmus, and optic atrophy are common. Neuropsychiatric disturbances including impulsivity, poor attention span, hyperactivity, and emotional lability are also common. The course is fairly stable during early childhood and resembles static encephalopathy but is followed by neurologic deterioration between ages seven and 12 years. PLA2G6-related dystonia-parkinsonism has a variable age of onset, but most individuals present in early adulthood with gait disturbance or neuropsychiatric changes. Affected individuals consistently develop dystonia and parkinsonism (which may be accompanied by rapid cognitive decline) in their late teens to early twenties. Dystonia is most common in the hands and feet but may be more generalized. The most common features of parkinsonism in these individuals are bradykinesia, resting tremor, rigidity, and postural instability.</Attribute>
                <XRef ID="NBK1675" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301718</ID>
                <ID Source="BookShelf">NBK1675</ID>
              </Citation>
              <XRef ID="329303" DB="Orphanet" />
              <XRef ID="CN204472" DB="MedGen" />
              <XRef ID="MONDO:0017998" DB="MONDO" />
            </Trait>
          </TraitSet>
          <TraitSet ID="10340" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="5628" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 2A</ElementValue>
                <XRef Type="MIM" ID="256600" DB="OMIM" />
                <XRef Type="Allelic variant" ID="603604.0001" DB="OMIM" />
                <XRef Type="Allelic variant" ID="603604.0007" DB="OMIM" />
                <XRef Type="Allelic variant" ID="603604.0003" DB="OMIM" />
                <XRef Type="Allelic variant" ID="603604.0006" DB="OMIM" />
                <XRef Type="Allelic variant" ID="603604.0014" DB="OMIM" />
                <XRef Type="Allelic variant" ID="603604.0015" DB="OMIM" />
                <XRef Type="Allelic variant" ID="603604.0004" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Infantile neuroaxonal dystrophy 1</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Seitelberger disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Infantile neuroaxonal dystrophy</ElementValue>
                <XRef ID="Neuroaxonal+dystrophy%2C+infantile/5159" DB="Genetic Alliance" />
                <XRef ID="52713000" DB="SNOMED CT" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">INAD1</ElementValue>
                <XRef Type="MIM" ID="256600" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Preferred">NBIA2A</ElementValue>
                <XRef Type="MIM" ID="256600" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">INAD</ElementValue>
                <XRef Type="MIM" ID="256600" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="3957" />
                <XRef ID="3957" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">PLA2G6-associated neurodegeneration (PLAN) comprises a continuum of three phenotypes with overlapping clinical and radiologic features: Infantile neuroaxonal dystrophy (INAD). Atypical neuroaxonal dystrophy (atypical NAD). PLA2G6-related dystonia-parkinsonism. INAD usually begins between ages six months and three years with psychomotor regression or delay, hypotonia, and progressive spastic tetraparesis. Many affected children never learn to walk or lose the ability shortly after attaining it. Strabismus, nystagmus, and optic atrophy are common. Disease progression is rapid, resulting in severe spasticity, progressive cognitive decline, and visual impairment. Many affected children do not survive beyond their first decade. Atypical NAD shows more phenotypic variability than INAD. In general, onset is in early childhood but can be as late as the end of the second decade. The presenting signs may be gait instability, ataxia, or speech delay and autistic features, which are sometimes the only evidence of disease for a year or more. Strabismus, nystagmus, and optic atrophy are common. Neuropsychiatric disturbances including impulsivity, poor attention span, hyperactivity, and emotional lability are also common. The course is fairly stable during early childhood and resembles static encephalopathy but is followed by neurologic deterioration between ages seven and 12 years. PLA2G6-related dystonia-parkinsonism has a variable age of onset, but most individuals present in early adulthood with gait disturbance or neuropsychiatric changes. Affected individuals consistently develop dystonia and parkinsonism (which may be accompanied by rapid cognitive decline) in their late teens to early twenties. Dystonia is most common in the hands and feet but may be more generalized. The most common features of parkinsonism in these individuals are bradykinesia, resting tremor, rigidity, and postural instability.</Attribute>
                <XRef ID="NBK1675" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">PLA2G6-Associated Neurodegeneration</Attribute>
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301718</ID>
                <ID Source="BookShelf">NBK1675</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">23447832</ID>
                <ID Source="BookShelf">NBK121988</ID>
              </Citation>
              <XRef ID="35069" DB="Orphanet" />
              <XRef ID="C0270724" DB="MedGen" />
              <XRef ID="MONDO:0024457" DB="MONDO" />
              <XRef Type="MIM" ID="256600" DB="OMIM" />
            </Trait>
            <Trait ID="5629" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">aNAD</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">atypical Neuroaxonal Dystrophy (aNAD)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Neurodegeneration with brain iron accumulation 2B</ElementValue>
                <XRef ID="MONDO:0012444" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">NEUROAXONAL DYSTROPHY, ATYPICAL</ElementValue>
                <XRef Type="MIM" ID="610217" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">NEURODEGENERATION WITH BRAIN IRON ACCUMULATION, PLA2G6-RELATED</ElementValue>
                <XRef Type="MIM" ID="610217" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">NBIA2B</ElementValue>
                <XRef Type="MIM" ID="610217" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10688" />
                <XRef ID="10688" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">PLA2G6-associated neurodegeneration (PLAN) comprises a continuum of three phenotypes with overlapping clinical and radiologic features: Infantile neuroaxonal dystrophy (INAD). Atypical neuroaxonal dystrophy (atypical NAD). PLA2G6-related dystonia-parkinsonism. INAD usually begins between ages six months and three years with psychomotor regression or delay, hypotonia, and progressive spastic tetraparesis. Many affected children never learn to walk or lose the ability shortly after attaining it. Strabismus, nystagmus, and optic atrophy are common. Disease progression is rapid, resulting in severe spasticity, progressive cognitive decline, and visual impairment. Many affected children do not survive beyond their first decade. Atypical NAD shows more phenotypic variability than INAD. In general, onset is in early childhood but can be as late as the end of the second decade. The presenting signs may be gait instability, ataxia, or speech delay and autistic features, which are sometimes the only evidence of disease for a year or more. Strabismus, nystagmus, and optic atrophy are common. Neuropsychiatric disturbances including impulsivity, poor attention span, hyperactivity, and emotional lability are also common. The course is fairly stable during early childhood and resembles static encephalopathy but is followed by neurologic deterioration between ages seven and 12 years. PLA2G6-related dystonia-parkinsonism has a variable age of onset, but most individuals present in early adulthood with gait disturbance or neuropsychiatric changes. Affected individuals consistently develop dystonia and parkinsonism (which may be accompanied by rapid cognitive decline) in their late teens to early twenties. Dystonia is most common in the hands and feet but may be more generalized. The most common features of parkinsonism in these individuals are bradykinesia, resting tremor, rigidity, and postural instability.</Attribute>
                <XRef ID="NBK1675" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301718</ID>
                <ID Source="BookShelf">NBK1675</ID>
              </Citation>
              <XRef ID="35069" DB="Orphanet" />
              <XRef ID="C1857747" DB="MedGen" />
              <XRef ID="MONDO:0012444" DB="MONDO" />
              <XRef Type="MIM" ID="610217" DB="OMIM" />
            </Trait>
            <Trait ID="6750" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Autosomal recessive Parkinson disease 14</ElementValue>
                <XRef ID="MONDO:0013060" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">DYSTONIA-PARKINSONISM, ADULT-ONSET</ElementValue>
                <XRef Type="MIM" ID="612953" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Parkinson disease 14</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">PARK14</ElementValue>
                <XRef Type="MIM" ID="612953" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="12568" />
                <XRef ID="12568" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301402</ID>
                <ID Source="BookShelf">NBK1223</ID>
              </Citation>
              <Citation Type="general" Abbrev="EFNS/MDS-ES, 2013">
                <ID Source="PubMed">23279440</ID>
              </Citation>
              <XRef ID="199351" DB="Orphanet" />
              <XRef ID="C2751842" DB="MedGen" />
              <XRef ID="MONDO:0013060" DB="MONDO" />
              <XRef Type="MIM" ID="612953" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="20141" Type="Finding" ContributesToAggregateClassification="true">
            <Trait ID="30555" Type="Finding">
              <Name>
                <ElementValue Type="Preferred">Iron accumulation in brain</ElementValue>
                <XRef ID="HP:0012675" DB="Human Phenotype Ontology" />
              </Name>
              <XRef ID="C4021076" DB="MedGen" />
              <XRef Type="primary" ID="HP:0012675" DB="Human Phenotype Ontology" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="342506" SubmissionDate="2014-09-11" DateLastUpdated="2014-11-23" DateCreated="2014-11-23">
        <ClinVarSubmissionID localKey="NM_003560.2(PLA2G6):c.1674del" />
        <ClinVarAccession Accession="SCV000194670" DateUpdated="2014-11-23" DateCreated="2014-11-23" Type="SCV" Version="1" SubmitterName="Genetic Services Laboratory, University of Chicago" OrgID="1238" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2014-03-17">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal recessive inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2007</Attribute>
          <Citation Type="general">
            <ID Source="PubMed">18414213</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="PLA2G6" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="22" start="38516834" />
          </Location>
          <AttributeSet>
            <Attribute Type="HGVS">NM_003560.2:c.1674del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Finding">
          <Trait Type="Finding">
            <Name>
              <ElementValue Type="Preferred">iron accumulation in brain</ElementValue>
            </Name>
            <XRef DB="MedGen" ID="CN185285" Type="CUI" />
            <XRef DB="HP" ID="HP:0012675" />
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5467823" SubmissionDate="2022-12-13" DateLastUpdated="2022-12-31" DateCreated="2022-12-31">
        <ClinVarSubmissionID localKey="NM_003560.4:c.1674del|OMIM:256600;610217;612953" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002816906" DateUpdated="2022-12-31" DateCreated="2022-12-31" Type="SCV" Version="1" SubmitterName="Fulgent Genetics, Fulgent Genetics" OrgID="500105" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-11-05">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_003560.4:c.1674del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="TraitChoice">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="256600" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="610217" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="612953" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12390657</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="6450160" SubmissionDate="2023-01-27" DateLastUpdated="2023-02-07" DateCreated="2023-02-07">
        <ClinVarSubmissionID localKey="b8a1b460-0773-4b7d-88bb-8e5f12346867" localKeyIsSubmitted="1" submittedAssembly="GRCh38" />
        <ClinVarAccession Accession="SCV003760982" DateUpdated="2023-02-07" DateCreated="2023-02-07" Type="SCV" Version="1" SubmitterName="Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard" OrgID="506627" OrganizationCategory="laboratory" OrgAbbreviation="Broad RDG" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-01-24">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
          <Comment>The p.Leu560fs variant in PLA2G6 has been reported in 3 individuals, in the compound heterozygous state, with PLA2G6-associated neurodegeneration (PMID: 27378808, 31196701, 24745848) and has been identified in 0.0009% (1/113656) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP ID: rs587784336). Although this variant has been seen in the general population in a heterozygous state, its frequency is low enough to be consistent with a recessive carrier frequency. This variant has also been reported in ClinVar (Variation ID#: 159742) and has been interpreted as pathogenic by Genetic Services Laboratory (University of Chicago). This variant is predicted to cause a frameshift, which alters the protein‚Äôs amino acid sequence beginning at position 560 and leads to a premature termination codon 5 amino acids downstream. This alteration is then predicted to lead to a truncated or absent protein. Loss of function of the PLA2G6 gene is an established disease mechanism in autosomal recessive PLA2G6-associated neurodegeneration. In summary, although additional studies are required to fully establish its clinical significance, this variant is likely pathogenic for autosomal recessive PLA2G6-associated neurodegeneration. ACMG/AMP Criteria applied: PVS1, PM2 (Richards 2015).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal recessive inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>curation</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="PLA2G6" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name>NM_003560.4(PLA2G6):c.1674del</Name>
            <Name>p.Leu560fs</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000022.11:g.38120830del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MONDO" ID="MONDO:0017998" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12627697</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="5467823" TraitType="Disease" MappingType="XRef" MappingValue="612953" MappingRef="OMIM">
        <MedGen CUI="C2751842" Name="Autosomal recessive Parkinson disease 14" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5467823" TraitType="Disease" MappingType="XRef" MappingValue="610217" MappingRef="OMIM">
        <MedGen CUI="C1857747" Name="Neurodegeneration with brain iron accumulation 2B" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5467823" TraitType="Disease" MappingType="XRef" MappingValue="256600" MappingRef="OMIM">
        <MedGen CUI="C0270724" Name="Infantile neuroaxonal dystrophy" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="342506" TraitType="Finding" MappingType="Name" MappingValue="iron accumulation in brain" MappingRef="Preferred">
        <MedGen CUI="C4021076" Name="Iron accumulation in brain" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="6450160" TraitType="Disease" MappingType="XRef" MappingValue="MONDO:0017998" MappingRef="MONDO">
        <MedGen CUI="CN204472" Name="PLA2G6-associated neurodegeneration" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

